Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Katherine TarlockXiaowei LiuCharles G MinardEmasenyie A IsikweiJoel M ReidTerzah M HortonElizabeth FoxBrenda J WeigelTodd M Cooper

Published in: Pediatric blood & cancer (2023)

combined with Aza-FLA was tolerable in children with R/R AML with similar toxicity profile to other intensive AML regimens. However, within the confines of a phase 1 study, we did not observe that the pevonedistat + Aza-FLA combination demonstrated significant anti-leukemic activity.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
young adults
clinical trial
high dose
double blind
hodgkin lymphoma
study protocol